Aster Capital Management DIFC Ltd Buys Shares of 8,990 DexCom, Inc. (NASDAQ:DXCM)

Aster Capital Management DIFC Ltd bought a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 8,990 shares of the medical device company's stock, valued at approximately $699,000.

Several other hedge funds also recently bought and sold shares of the stock. Geode Capital Management LLC boosted its position in shares of DexCom by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 9,993,698 shares of the medical device company's stock worth $775,256,000 after purchasing an additional 56,094 shares during the period. Jennison Associates LLC boosted its position in shares of DexCom by 10.3% during the fourth quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after buying an additional 710,858 shares during the period. Norges Bank acquired a new stake in shares of DexCom in the fourth quarter valued at $385,367,000. Groupama Asset Managment raised its holdings in shares of DexCom by 1.1% in the 3rd quarter. Groupama Asset Managment now owns 2,851,556 shares of the medical device company's stock valued at $1,912,000 after buying an additional 31,358 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its stake in DexCom by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,825,206 shares of the medical device company's stock worth $219,716,000 after acquiring an additional 91,051 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Down 1.8 %

Shares of DexCom stock traded down $1.21 during trading hours on Friday, hitting $66.09. The company had a trading volume of 1,602,458 shares, compared to its average volume of 4,167,691. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The company's 50-day moving average is $77.35 and its two-hundred day moving average is $76.62. The company has a market cap of $25.92 billion, a P/E ratio of 46.21, a price-to-earnings-growth ratio of 2.30 and a beta of 1.50. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $141.25.

Remove Ads

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 14,076 shares of DexCom stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the transaction, the chief operating officer now directly owns 313,497 shares in the company, valued at approximately $22,063,918.86. The trade was a 4.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the sale, the executive vice president now owns 105,602 shares of the company's stock, valued at $7,432,268.76. This trade represents a 10.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 105,009 shares of company stock worth $8,044,178 in the last quarter. 0.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on DXCM shares. Cfra Research raised DexCom to a "hold" rating in a research report on Friday, March 21st. Baird R W raised shares of DexCom from a "hold" rating to a "strong-buy" rating in a research note on Thursday, January 16th. Morgan Stanley upped their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Citigroup increased their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a "buy" rating in a report on Tuesday, March 4th. Finally, Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, DexCom currently has an average rating of "Moderate Buy" and a consensus price target of $99.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.